Phase II, Randomized, Double-blinded, Placebo-Control, Toxicity/Efficacy Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdcuCD40L) to Patients With Stage I, II or III Esophageal Carcinoma
This study is designed to add to the safety profile data as well as assessing biologic
efficacy parameters. It will include 24 individuals with biopsy proven, resectable, stage
I-III esophageal cancer. Because there may be immune responses attributable to the gene
therapy vector itself, independent of the CD40L transgene, this part of the study is
designed in a randomized, blinded fashion to compare intratumoral administration of the
AdcuCD40L vector compared to a placebo. Because there are likely differences over time in
the pattern of the biologic response to the expression of CD40L in the tumor (including
activation and trafficking of DC, and recruitment and activation of immune cells), this
study will include 2 "time" cohorts (based on the time between administration of the
AdcuCD40L vector and the time of surgery to remove the tumor). Using Weill-IRB protocol
#0011004683 dose escalation study to determine the highest non-toxic dose of the AdcuCD40L
vector, this dose (likely 10^11 particle units) will be used for all individuals enrolled in
this efficacy study. The placebo will be the salt water-sugar solution used as a vehicle for
the vector. Since there is no evidence that delay of surgery for solid tumors for 15 days
following diagnosis alters the prognosis, surgery for removal of the primary tumor will be
carried out at either 5 or 15 days after administration of the vector (n= 12/group,
including n=6 receiving the AdcuCD40L vector, and n=6 receiving placebo). This will permit
assessment of the resulting data (in a randomized, blinded fashion) and the biologic
responses to the AdCUCD40L vector over time. In addition to safety/toxicity parameters, the
primary tumor, regional and distant nodes removed at the time of surgery, and peripheral
blood will be assessed for biologic parameters relevant to responses to the AdcuCD40L
vector.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Expression of CD40L and cytokines
5-15 days
No
Ronald G. Crystal, MD
Principal Investigator
Department of Genetic Medicine
United States: Food and Drug Administration
0502007770
NCT00504322
July 2011
July 2011
Name | Location |
---|---|
Weill Medical College of Cornell University | New York, New York 10021 |
The Valley Hospital | Paramus, New Jersey 07652 |